Pyrrolyl and Indolyl α-γ-Diketo Acid Derivatives Acting as Selective Inhibitors of Human Carbonic Anhydrases IX and XII

Author:

Ialongo Davide1ORCID,Messore Antonella1,Madia Valentina Noemi1ORCID,Tudino Valeria1,Nocentini Alessio2ORCID,Gratteri Paola2ORCID,Giovannuzzi Simone3,Supuran Claudiu T.3ORCID,Nicolai Alice4,Scarpa Susanna4ORCID,Taurone Samanta5ORCID,Camarda Michele6,Artico Marco6ORCID,Papa Veronica7ORCID,Saccoliti Francesco8,Scipione Luigi1ORCID,Di Santo Roberto1ORCID,Costi Roberta1

Affiliation:

1. Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome, p.le Aldo Moro 5, I-00185 Rome, Italy

2. Laboratory of Molecular Modeling Cheminformatics & QSAR, NEUROFARBA Department, University of Florence, Via U. Schiff 6, Sesto Fiorentino, 50019 Firenze, Italy

3. NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Via U. Schiff 6, Sesto Fiorentino, 50019 Firenze, Italy

4. Dipartimento Medicina Sperimentale, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

5. Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy

6. Department of Sensory Organs, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy

7. Department of Motor Sciences and Wellness, University of Naples “Partenope”, 80133 Naples, Italy

8. D3 PharmaChemistry, Italian Institute of Technology, Via Morego 30, 16163 Genova, Italy

Abstract

Solid tumors are active tissues containing hypoxic regions and producing metabolic acids. By decreasing pH, cancer cells create a hostile environment for surrounding host cells and foster tumor growth and progression. By governing acid/base regulation, carbonic anhydrases (CAs) are involved in several physiological/pathological processes, including tumors. Indeed, CAs are clinically relevant in cancer therapy as among the fifteen human isoforms, two of them, namely CA IX (overexpressed in solid tumors and associated with increased metastasis and poor prognosis) and CA XII (overexpressed in some tumors) are involved in tumorigenesis. Targeting these two isoforms is considered as a pertinent approach to develop new cancer therapeutics. Several CA inhibitors (CAIs) have been described, even though they are unselective inhibitors of different isoforms. Thus, efforts are needed to find new selective CAIs. In this work, we described new diketo acid derivatives as CAIs, with the best acting compounds 1c and 5 as nanomolar inhibitors of CA IX and XII, being also two orders of magnitude selective over CAs I and II. Molecular modeling studies showed the different binding poses of the best acting CAIs within CA II and IX, highlighting the key structural features that could confer the ability to establish specific interactions within the enzymes. In different tumor cell lines overexpressing CA IX and XII, the tested compounds showed antiproliferative activity already at 24 h treatment, with no effects on somatic not transformed cells.

Funder

“Sapienza” Ateneo 2019

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3